Related Experiment Video
Updated: Mar 24, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study
Laura Lattanzio1, Gerard Milano, Martino Monteverde
1aLaboratory of Cancer Genetics and Translational Oncology and Medical Oncology, Oncology Department, S. Croce and Carle Teaching Hospital, Cuneo, Italy bOncopharmacology Unit, Centre Antoine Lacassagne, Nice, France.
Abstract:
Aberrant epidermal growth factor receptor (EGFR) signaling is associated with tumor growth in head and neck squamous cell carcinoma (HNSCC) and is a major focus of targeted therapy. The phosphatidylinositol-3-kinase/AKT/mammalian target of the rapamycin (PI3K/AKT/mTOR) signaling pathway is frequently mutated in HNSCC and is involved in disease progression and resistance to EGFR inhibitors. The aim of this study was to assess the antiproliferative effects of mTOR inhibition (temsirolimus) combined with the anti-EGFR monoclonal antibody cetuximab, administered according to different combination schedules. Antiproliferative effects of the combination of temsirolimus and cetuximab were determined on the representative HNSCC CAL33 cell line (PI3KCA H1047R mutated and K-RAS wild-type). In addition, key proteins related to the EGFR pathway (pEGFR/EGFR, pAKT/AKT) and the mTOR pathway (p-p70S6K1, p4E-BP1) were determined to explain the cytotoxic effects. Temsirolimus and cetuximab showed a synergistic effect when administered in combination. Supra-additive effect was lost when the two drugs were administered sequentially, irrespective of which drug was administered first. Synergistic effect of the combination was corroborated by a marked downregulation of pEGFR, significant downregulation of pAKT expression, and a marked diminution of p70S6K1 and p4E-BP1 expression. Our study demonstrated a synergistic effect of temsirolimus and cetuximab administered in combination, well illustrated by a simultaneous blockade of intracellular signaling pathways regulating cell proliferation and survival. These results establish the notion of a schedule dependency for the combined treatment, which can be of importance at the clinical level.
Insights
Combining temsirolimus and cetuximab shows synergistic effects against head and neck squamous cell carcinoma (HNSCC). Optimal results depend on simultaneous administration, highlighting schedule dependency for this targeted therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Aberrant epidermal growth factor receptor (EGFR) signaling drives head and neck squamous cell carcinoma (HNSCC) growth.
- The PI3K/AKT/mTOR pathway is frequently altered in HNSCC, contributing to progression and resistance to EGFR inhibitors.
Purpose of the Study:
- To evaluate the antiproliferative effects of combining mTOR inhibitor temsirolimus with anti-EGFR antibody cetuximab in HNSCC.
- To determine the optimal administration schedule for temsirolimus and cetuximab combination therapy.
Main Methods:
- Antiproliferative effects were assessed on the HNSCC CAL33 cell line.
- Key protein expressions in EGFR and mTOR pathways (pEGFR, pAKT, p70S6K1, 4E-BP1) were analyzed to correlate with cytotoxic effects.
Main Results:
- Temsirolimus and cetuximab demonstrated synergistic antiproliferative effects when administered concurrently.
- Sequential administration, regardless of order, abolished the supra-additive effect.
- Combination therapy led to downregulation of pEGFR, pAKT, p70S6K1, and 4E-BP1, indicating pathway blockade.
Conclusions:
- Simultaneous administration of temsirolimus and cetuximab yields synergistic effects in HNSCC by blocking key survival pathways.
- Treatment schedule is critical for maximizing the efficacy of this combination therapy in a clinical setting.
